Literature DB >> 22840735

Introduction of laser technology and procedure use for benign prostatic hyperplasia: data from Florida.

Florian R Schroeck1, John M Hollingsworth, Samuel R Kaufman, Brent K Hollenbeck, John T Wei.   

Abstract

OBJECTIVE: To examine the association of laser technology adoption in a market with surgery rates for benign prostatic hyperplasia.
METHODS: Using the Florida files from the State Ambulatory and Inpatient Surgery Databases (2001-2009), we identified all patients who underwent transurethral surgery for benign prostatic hyperplasia. We calculated rates of benign prostatic hyperplasia surgery for all markets within the state (defined by Hospital Service Area) over time. Markets were split into 3 categories: (1) Always offering, (2) never offering, or (3) initially not offering but adopting laser prostatectomy after 2001. We used multivariable regression models to estimate surgery rates adjusted for other market characteristics. Interaction terms were included in the models to examine differences in time trends between market categories.
RESULTS: After adjusting for market characteristics, time trends differed by market category (P < .001). Surgery rates decreased from 318 to 248 procedures per 100,000 men in markets always offering laser prostatectomy (P < .001). Markets never offering laser surgery had much lower rates that remained stable (180-187 procedures per 100,000 men, P = .805). In markets adopting laser technology, rates increased from 268 to 296 procedures per 100,000 men after adoption (P = .044), such that 4 years after adoption these markets had the highest rates among the 3 categories.
CONCLUSION: Adoption of laser technology is associated with rising rates of surgical intervention for benign prostatic hyperplasia. This trend appears to be induced by the introduction of laser surgery.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22840735      PMCID: PMC3429633          DOI: 10.1016/j.urology.2012.05.025

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  21 in total

1.  Technology evolution: is it survival of the fittest?

Authors:  Anthony Zietman; Michael Goitein; Joel E Tepper
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

2.  Opening ambulatory surgery centers and stone surgery rates in health care markets.

Authors:  John M Hollingsworth; Sarah L Krein; John D Birkmeyer; Zaojun Ye; Hyungjin Myra Kim; Yun Zhang; Brent K Hollenbeck
Journal:  J Urol       Date:  2010-09       Impact factor: 7.450

3.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

4.  The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease.

Authors:  S R Tunis; E B Bass; E P Steinberg
Journal:  N Engl J Med       Date:  1991-08-22       Impact factor: 91.245

Review 5.  Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction.

Authors:  Natasha Burke; J Paul Whelan; Linda Goeree; Robert B Hopkins; Kaitryn Campbell; Ron Goeree; Jean-Eric Tarride
Journal:  Urology       Date:  2009-10-24       Impact factor: 2.649

6.  The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.

Authors:  David A Taub; John T Wei
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

7.  Economic evaluation of treatment strategies for benign prostatic hyperplasia--is medical therapy more costly in the long run?

Authors:  Christopher S Saigal; Mehran Movassaghi; Jennifer Pace; Geoffrey Joyce
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

8.  Economic costs of benign prostatic hyperplasia in the private sector.

Authors:  Christopher S Saigal; Geoffrey Joyce
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

9.  Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies.

Authors:  Xinhua Yu; Sean P Elliott; Timothy J Wilt; A Marshall McBean
Journal:  J Urol       Date:  2008-05-21       Impact factor: 7.450

10.  Mortality among hospitalized Medicare beneficiaries in the first 2 years following ACGME resident duty hour reform.

Authors:  Kevin G Volpp; Amy K Rosen; Paul R Rosenbaum; Patrick S Romano; Orit Even-Shoshan; Yanli Wang; Lisa Bellini; Tiffany Behringer; Jeffrey H Silber
Journal:  JAMA       Date:  2007-09-05       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.